NURPF Stock Latest News
Company AnnouncementsNeuren’s Rett Drug Trofinetide Gains U.S. Patent Extension to 20411M ago
Company AnnouncementsNeuren updates currency handling for June 2026 dividend1M ago
Company AnnouncementsNeuren Highlights Neurodevelopment Focus and Development Risks2M ago- Company AnnouncementsNeuren Pharmaceuticals Earnings Call Signals Cash-Fueled Growth2M ago
Company AnnouncementsNeuren Pharmaceuticals Declares Interim Dividend for June 2026 Half2M ago
Company AnnouncementsNeuren launches first dividend as DAYBUE royalties and rare-disease pipeline gather pace2M ago
- Company AnnouncementsNeuren to Brief Investors on H1 2026 Results as Rare Neurology Pipeline Advances2M ago
Company AnnouncementsNeuren lifts royalty outlook as DAYBUE sales hit record and global rollout advances2M ago
Company AnnouncementsNeuren deepens rare disease push as Phase 3 PMS trial gains momentum3M ago
Company AnnouncementsNeuren Set for Major EU Milestone as EMA Backs DAYBU for Rett Syndrome4M ago
Company AnnouncementsNeuren Pharmaceuticals Seeks ASX Quotation for 450,000 New Shares4M agoCompany AnnouncementsNeuren Investors Back Board and CEO Options but Reject Constitution Changes5M ago
Company AnnouncementsNeuren Leverages DAYBUE Windfall to Drive NNZ-2591 Phase 3 Push in Rare Neurological Disorders5M ago- Company AnnouncementsNeuren Advances NNZ-2591 Into Phase 3 Extension, Deepening Its Rare-Disease Pipeline5M agoNURPF
Company AnnouncementsNeuren launches Investor Hub to bolster engagement as neurological pipeline advances5M ago
Company AnnouncementsNeuren Pharmaceuticals Updates Daily On‑Market Share Buy‑Back Activity5M ago
Company AnnouncementsNeuren Rides 20% DAYBUE Sales Growth and Strong STIX Launch in Q1 20265M agoCompany AnnouncementsNeuren Pharmaceuticals Outlines Procedures for Virtual Shareholder Meeting6M ago